Guardant Health, headquartered in Redwood City, Calif., is developing breakthrough diagnostics to transform cancer from a silent killer into a manageable disease. The company is the liquid biopsy market leader and has raised $100 million from Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, and others. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics, and cancer diagnostics and its first product, Guardant360®, came to market in 2014. The team is committed to improving patient health through technology that addresses long-standing unmet needs in oncology. The World Economic Forum named Guardant Health a 2015 Technology Pioneer.